JP2022542434A5 - - Google Patents
Info
- Publication number
- JP2022542434A5 JP2022542434A5 JP2022506384A JP2022506384A JP2022542434A5 JP 2022542434 A5 JP2022542434 A5 JP 2022542434A5 JP 2022506384 A JP2022506384 A JP 2022506384A JP 2022506384 A JP2022506384 A JP 2022506384A JP 2022542434 A5 JP2022542434 A5 JP 2022542434A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cancers
- syndrome
- vitiligo
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881026P | 2019-07-31 | 2019-07-31 | |
| US62/881,026 | 2019-07-31 | ||
| PCT/US2020/044558 WO2021022186A1 (en) | 2019-07-31 | 2020-07-31 | Deuterated mk2 pathway inhibitors and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022542434A JP2022542434A (ja) | 2022-10-03 |
| JP2022542434A5 true JP2022542434A5 (cg-RX-API-DMAC7.html) | 2023-07-19 |
Family
ID=74228512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506384A Ceased JP2022542434A (ja) | 2019-07-31 | 2020-07-31 | 重水素化mk2経路阻害剤およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12403141B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4003344A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022542434A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220041180A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114206339A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020319879A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022001324A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3149304A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290045A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022001151A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022550029A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021022186A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296054A (en) | 2020-03-27 | 2022-10-01 | Aclaris Therapeutics Inc | Oral compositions of mk2 pathway inhibitor for treatment of immune conditions |
| WO2022212489A1 (en) | 2021-03-31 | 2022-10-06 | Xinthera, Inc. | Mk2 inhibitors and uses thereof |
| US11685719B2 (en) | 2021-07-09 | 2023-06-27 | Xinthera, Inc. | Pyridinone MK2 inhibitors and uses thereof |
| WO2023001282A1 (zh) * | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 杂环取代的嘧啶衍生物 |
| CN116444492B (zh) * | 2021-12-29 | 2026-03-03 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN116396274B (zh) * | 2022-01-06 | 2025-11-11 | 深圳信立泰药业股份有限公司 | 一种取代的联吡啶酮类化合物及其制备方法与应用 |
| CN116444493A (zh) * | 2022-01-14 | 2023-07-18 | 上海翰森生物医药科技有限公司 | 含双并环类衍生物、其制备方法和应用 |
| EP4464694A4 (en) | 2022-01-14 | 2026-04-01 | Shanghai Hansoh Biomedical Co Ltd | POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE |
| US20230286950A1 (en) * | 2022-02-04 | 2023-09-14 | Aclaris Therapeutics, Inc. | Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds |
| CN119384410B (zh) * | 2022-03-03 | 2026-06-12 | 深圳信立泰药业股份有限公司 | 一种氘代三联吡啶二酮化合物或其盐及其制备方法与应用 |
| US20260217652A1 (en) * | 2023-01-13 | 2026-07-30 | Shanghai Meiyue Biotech Development Co., Ltd. | Phenyl-substituted heteroaryl compound and pharmaceutical composition comprising same, preparation method therefor and use thereof |
| JP2026504073A (ja) * | 2023-01-13 | 2026-02-03 | プールベグ ファーマ(ユーケー) リミテッド | がん免疫療法関連サイトカイン放出症候群の軽減のための医薬品および方法 |
| WO2025093869A1 (en) * | 2023-11-01 | 2025-05-08 | Poolbeg Pharma (UK) Limited | P38 map kinase inhibitor for use in the treatment of inflammation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080280886A1 (en) * | 2007-05-08 | 2008-11-13 | Auspex Pharmaceuticals, Inc. | Substituted ureas |
| CA2763565A1 (en) * | 2009-05-28 | 2010-12-02 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
| US8575348B2 (en) * | 2009-07-28 | 2013-11-05 | Auspex Pharmaceuticals, Inc | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
| DK2648516T3 (da) * | 2010-12-06 | 2019-01-02 | Aclaris Therapeutics Inc | Substituerede pyridinon-pyridinylforbindelser |
| US9359300B2 (en) * | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
| KR102313515B1 (ko) | 2013-06-07 | 2021-10-14 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 메틸/플루오로-피리디닐-메톡시 치환된 피리디논-피리디닐 화합물 및 플루오로-피리미디닐-메톡시 치환된 피리디논-피리디닐 화합물 |
| CZ2015601A3 (cs) * | 2015-09-02 | 2017-03-15 | Zentiva, K.S. | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty |
| AU2017250086A1 (en) * | 2016-04-11 | 2018-09-20 | Clexio Biosciences Ltd. | Deuterated ketamine derivatives |
| WO2018229683A1 (en) * | 2017-06-15 | 2018-12-20 | Novartis Ag | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
| CN111727042A (zh) * | 2017-12-06 | 2020-09-29 | 仁新医药私人有限公司 | 微管蛋白抑制剂 |
| WO2021178449A1 (en) | 2020-03-02 | 2021-09-10 | Washington University | Compositions and methods for the treatment of pancreatic cancer |
-
2020
- 2020-07-31 CN CN202080051376.9A patent/CN114206339A/zh active Pending
- 2020-07-31 BR BR112022001324A patent/BR112022001324A2/pt not_active IP Right Cessation
- 2020-07-31 CA CA3149304A patent/CA3149304A1/en active Pending
- 2020-07-31 US US17/630,414 patent/US12403141B2/en active Active
- 2020-07-31 AU AU2020319879A patent/AU2020319879A1/en not_active Abandoned
- 2020-07-31 EP EP20847487.4A patent/EP4003344A4/en not_active Withdrawn
- 2020-07-31 JP JP2022506384A patent/JP2022542434A/ja not_active Ceased
- 2020-07-31 WO PCT/US2020/044558 patent/WO2021022186A1/en not_active Ceased
- 2020-07-31 MX MX2022001151A patent/MX2022001151A/es unknown
- 2020-07-31 KR KR1020227006713A patent/KR20220041180A/ko not_active Ceased
- 2020-07-31 PH PH1/2022/550029A patent/PH12022550029A1/en unknown
-
2022
- 2022-01-23 IL IL290045A patent/IL290045A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022531088A5 (cg-RX-API-DMAC7.html) | ||
| JP2021534244A5 (cg-RX-API-DMAC7.html) | ||
| ES2985542T3 (es) | Compuesto inhibidor de JAK y uso del mismo | |
| JP7580136B2 (ja) | Jak阻害剤化合物及びその使用 | |
| JP2021502400A5 (cg-RX-API-DMAC7.html) | ||
| JP2020512315A5 (cg-RX-API-DMAC7.html) | ||
| JP2020511468A5 (cg-RX-API-DMAC7.html) | ||
| ES2277858T3 (es) | Heterociclos de nitrogeno biciclicos alquilamino sustituidos como inhibidores de proteina kinasa p38. | |
| DE60209381T2 (de) | N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase | |
| JP2022137194A (ja) | 神経刺激性ステロイド、組成物、およびその使用 | |
| JP2020128420A (ja) | Cns障害を処置するための組成物および方法 | |
| DE69920732T2 (de) | Bicyclische stickstoffheteroaryl verbindungen | |
| TWI842766B (zh) | 三環janus 激酶1 抑制劑及其組合物和方法 | |
| ES2430210T3 (es) | Derivados de 4-aminopirimidina como antagonistas del receptor de histamina H4 | |
| JP2017529367A5 (cg-RX-API-DMAC7.html) | ||
| EA027879B1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK) | |
| CN111689959A (zh) | 作为fgfr4抑制剂的杂环化合物 | |
| CN113166193A (zh) | 用于治疗cns病症的在位置10处被环状基团取代的神经活性类固醇 | |
| CN113993585B (zh) | 双环jak抑制剂及其用途 | |
| JP2022551316A5 (cg-RX-API-DMAC7.html) | ||
| TW202227448A (zh) | 製備jak抑制劑之方法及中間體 | |
| JP7164619B2 (ja) | 新規ブラジキニンb2受容体アンタゴニスト | |
| CN120904157A (zh) | 杂芳基化合物及其制备方法和用途 | |
| CN118702683A (zh) | 吡唑基-氨基-嘧啶基衍生物的苯醚和苯胺及其组合物和方法 | |
| AU2019206560B2 (en) | Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators |